Dr. Kantoff on the Rationale to Evaluate VERU-111 in mCRPC
Philip W. Kantoff, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.
Philip W. Kantoff, MD, chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care® winner for Genitourinary Cancer, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer (mCRPC).
VERU-111 is an oral tubulin inhibitor, says Kantoff. Taxanes, such as docetaxel and cabazitaxel (Jevtana), are also active against tubulin, Kantoff explains.
Although taxanes and VERU-111 are active against tubulin, their distinct mechanisms of action are not fully defined, explains Kantoff.
Currently, taxanes have demonstrated modest activity in patients with mCRPC, although docetaxel has shown significant activity in the metastatic hormone-sensitive setting, Kantoff concludes.
